AI-powered genomic and clinical data intelligence company GeneDx (formerly Sema4) plans to raise USD 150 million via an underwritten public offering consisting of 428.6 million common shares priced at USD 0.35 per share. The offering includes a direct offering of 100 million shares to an institutional investor. The firm will also offer a 30-day option to underwriters to purchase an additional 49.3 million common shares. The offering is expected to close by January 31, 2023, subject to regulatory approval.
The sole book-running manager of the offering and placement agent of the direct offering is Jefferies, while GeneDx’s financial advisor is Cowen.
The new funds will be used toward general corporate expenses including working capital, repayment of debts, and strategic investments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.